Product Description
a human IgG1kappa anti-CCL2 mAb (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24928772/)
Mechanisms of Action: CCL2 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Centocor
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostate Cancer|Idiopathic Interstitial Pneumonias|Idiopathic Pulmonary Fibrosis
Phase 1: Hypertension|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2008-001281-86 | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2012-08-14 |
|
| 2009-011250-17 | P2 |
Completed |
Unknown |
2010-07-14 |
|
| 2009-011251-48 | P2 |
Completed |
Prostate Cancer |
2011-07-06 |
|
| CR013699 | P1 |
Completed |
Hypertension |
None |
|
| CR015235 | P2 |
Completed |
Idiopathic Pulmonary Fibrosis|Idiopathic Interstitial Pneumonias |
2012-01-01 |
|
| CR015907 | P2 |
Completed |
Prostate Cancer |
2011-07-01 |
|
| CR016462 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
None |